inozyme_logo.jpg
Inozyme Pharma Announces Three Poster Presentations at the American Society for Bone and Mineral Research (ASBMR) 2023 Annual Meeting
October 06, 2023 08:30 ET | Inozyme Pharma Inc.
BOSTON, Oct. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) (“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
inozyme_logo.jpg
Inozyme Pharma Announces Positive Interim Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE)
September 26, 2023 07:30 ET | Inozyme Pharma Inc.
- Data from ongoing trial suggest clinical benefit for ENPP1 Deficiency, including improvement in key biomarkers, patient reported outcomes (PROs) and functional outcomes - - Improvement in the...
inozyme_logo.jpg
Inozyme Pharma to Host Virtual Investor and Analyst Event on Sep. 26, 2023
September 20, 2023 08:30 ET | Inozyme Pharma Inc.
BOSTON, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Inozyme” or the “Company”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for...
inozyme_logo.jpg
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2023 08:30 ET | Inozyme Pharma Inc.
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY)(“Company” or “Inozyme”), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the...
inozyme_logo.jpg
Inozyme Pharma to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 08:30 ET | Inozyme Pharma Inc.
BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
inozyme_logo.jpg
Inozyme Pharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
August 08, 2023 08:30 ET | Inozyme Pharma Inc.
– Interim data readouts from ongoing Phase 1/2 trials of INZ-701 in adults with ENPP1 Deficiency and ABCC6 Deficiency expected in September 2023 – – Plasma pyrophosphate (PPi) to...
inozyme_logo.jpg
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 03, 2023 16:01 ET | Inozyme Pharma Inc.
BOSTON, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
inozyme_logo.jpg
Inozyme Pharma, Inc. Announces Closing of Public Offering of Common Stock
August 01, 2023 16:01 ET | Inozyme Pharma Inc.
BOSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
inozyme_logo.jpg
Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
July 27, 2023 23:20 ET | Inozyme Pharma Inc.
BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...
inozyme_logo.jpg
Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock
July 27, 2023 16:33 ET | Inozyme Pharma Inc.
BOSTON, July 27, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic...